Imprivata enters into contract with Texas Instruments
Leader in healthcare IT security Imprivata and Texas Instruments Incorporated has signed an agreement to support strong authentication and secure application access from virtual desktop environments.
The solution, combining TI’s DM8148 system-on-chip and Imprivata OneSign will enable manufacturers to provide out-of-the-box strong user authentication into any software application delivered through a thin-or-zero-client endpoint.
This type of integrated technology is attractive in healthcare, where the highly mobile care providers need fast, secure access to sensitive patient information on shared devices.
The Texas Instrument’s cost-effective DM8148 SoC drives optimized virtual capabilities in power efficient and secured manner.
The SoC drives the optimized virtual desktop capabilities in the secured and power efficient manner. It also supports dual-displays running concurrently upto 1920x1200 resolution.
The DM8148 also supports the leading Virtual Desktop Infrastructure protocols for ultimate flexibility. The low-power SoC enables OEMs to create a fanless design that yields greater reliability and lower maintenance for thin-client systems.
Texas Instruments has also developed a software reference design kit for thin and zero clients. Through its partnership with TI, Imprivata enables thin and zero client vendors to embed Imprivata OneSign strong authentication functionality directly into their devices incorporating the TIDM8148 SoC.
Imprivata is the number one provider of secure access solutions for healthcare. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, the customers realize improved workflows, increased security and compliance along with government regulations.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”